News
KTRA
0.1040
+16.20%
0.0145
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 11h ago
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company's shares jumped 9.4% to $324.99 in pre-market trading. Avalo Therapeutics, Inc. Gained 256.6% on Wednesday.
Benzinga · 17h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. Xilio Therapeutic (XLO) stock moved upwards by 223.94% during the session. Akanda (AKAN) shares increased by 27.1% and INVO Bioscience (INVO) stock increased by 16.36%. NuCana (NCNA) stock declined by 19.8% in the pre- market.
Benzinga · 18h ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Moving stocks this morning are public debuts, earnings reports and more. Avalo Therapeutics stock is rocketing more than 268% after going public yesterday. Urban-gro stock is diving more than 18% with the release of its latest earnings report. 10 of the biggest pre-market stock movers are in the biotech sector.
Investorplace · 18h ago
Kintara Expands Clinical Study with Pembrolizumab
TipRanks · 1d ago
Weekly Report: what happened at KTRA last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at KTRA last week (0311-0315)?
Weekly Report · 03/18 10:25
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Aptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. Nuvectis Pharma and Bright Green are among the companies that moved upwards in the day's trading. The Q4 earnings report came out yesterday.
Benzinga · 03/14 13:06
HEAR, SOUN and WW are among after hour movers
On the Move HEAR, SOUN and WW are among after hour movers. Turtle Beach (HEAR) and SoundHound (SOUN) are among the biggest gainers. WW International (WW) and Vroom (VRM) are the biggest losers.
Seeking Alpha · 03/13 21:07
12 Health Care Stocks Moving In Wednesday's Intraday Session
Heron Therapeutics shares rose 35.4% to $3.19 during Wednesday's regular session. The company's, Q4 earnings came out yesterday. Trxade Health (NASDAQ:MEDS) shares fell 22.6% during the session. NuCana stock rose 34.32% and Cardiff Oncology shares increased by 27.9%.
Benzinga · 03/13 17:31
What's Going On With Kintara Therapeutics Stock?
Kintara Therapeutics, Inc. Shares are moving on heavy trading volume after the company announced it is seeking withdrawal of its registration statement for a public offering of securities. More than 100 million shares have already been traded in the session. Shares of Kintara have decreased by 97.05% in the past year.
Benzinga · 03/13 17:21
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Clover Health Investments, Corp. Shares jumped 11.2% to $0.8537 on Wednesday. The company reported better-than-expected fourth-quarter revenue results. Gaxos.ai shares jumped 128.9% after the company acquired rights to use certain AI-enabled technology from Ultiself. Veritone, Inc. And The Beauty Health Company also gained.
Benzinga · 03/13 17:18
HRTX, LUNA and ARQ among mid-day movers
On the Move HRTX, LUNA and ARQ among mid-day movers. Gaxos.AI and MicroCloud Hologram are among the Gainers. 1847 Holdings and Luna Innovations were among the losers in SA's list of companies.
Seeking Alpha · 03/13 17:18
Reported Earlier, Kintara Therapeutics Filed FormRW Seeking Withdrawal Of The Registration Statement As It Does Not Intend To Pursue The Contemplated Public Offering Of The Securities Covered By The Registration Statement At This Time; Registration Statement Has Not Been Declared Effective And No Securities Of The Co Were Sold Pursuant To The Registration Statement
Benzinga · 03/13 16:57
US Stocks Mixed; Williams-Sonoma Earnings Top Views
Williams-Sonoma posted better-than-expected earnings for its fourth quarter on Wednesday. Energy shares jumped by 1.6% on Wednesday while information technology shares fell by 0.9%. The Dow traded up 0.08% and the Nasdaq Composite fell around 50 points. Asian markets closed lower on Wednesday; European shares were higher.
Benzinga · 03/13 13:49
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. HUTCHMED (China) stock increased by 14.04% in the pre- market session. Kintara Therapeutics (NASdaq:KTRA) and Qilian Intl. Gr (Qilian) were among the losers.
Benzinga · 03/13 13:06
Weekly Report: what happened at KTRA last week (0304-0308)?
Weekly Report · 03/11 10:23
Weekly Report: what happened at KTRA last week (0226-0301)?
Weekly Report · 03/04 10:25
Weekly Report: what happened at KTRA last week (0219-0223)?
Weekly Report · 02/26 10:33
More
Webull provides a variety of real-time KTRA stock news. You can receive the latest news about Kintara Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KTRA
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.